Healthy subjects
Conditions
Interventions
Subjects are administrated rabeprazole 20mg after administrated vonoprazan 20mg.
Subjects are administrated vonoprazan 20mg after administrated rabeprazole 20mg.
Subjects are administrated rabeprazole
Sponsors
Osaka medical collage
Gunma University,Yokohama City University,Hamamatsu University School of Medicine,Aichi Medical University,Osaka City University,Saga University,Oita University,University of Miyazaki,Shiga University of Medical Science,Okayama University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 20 years of age or more
Exclusion criteria
Exclusion criteria: 1) by constriction or deformation of the upper gastrointestinal tract, drug administration and the endoscope insertion difficult. 2) there is a history of acid-related diseases. 3) there is a surgical history. 4) there is a history of radiation therapy to the upper abdomen. 5) serious complications(with heart failure, kidney failure, liver failure, respiratory failure). 6) Experience of oral administration of Vonoprazan or Rabeprazole. 7) there is a history of medication to up to one month before the registration date. 8) there is a history eradication of Helicobacter pylori. 9) Helicobacter pylori test positive (anti-HP IgG antibody, urease test, any one is positive urea breath test). 10) There is activity malignant tumor patients and other serious systemic complication. 11) there are abnormal findings in the upper gastrointestinal endoscopy. 12) F scale positive (total score 8 points or more) 13) There is a history of allergy to test drugs 14) pregnancy and lactation. 15) there is a plan of treatment with respect to the upper gastrointestinal tract disease. 16) there is a registration history in the study. 17) can not be obtained the consent to participate in this clinical study. 18) the study director (sharing) who doctor has determined to be inappropriate as a subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate that vonoprazan show a signifcant acid suppressant effect against rabeprazole by comparing an acid suppressant effect on gastric pH (pH holding time at no less than pH3, pH4, and pH5) between vonoprazan and rabeprazole | — |
Secondary
| Measure | Time frame |
|---|---|
| Acid suppressant effect by the CYP2C19 genetic polymorphism. Nighttime acid suppressant effect. An incidence of all adverse events. Acid suppressant effect before and after a meal. | — |
Countries
Japan
Contacts
Public ContactYuichi Kojima
Osaka medical collage second department of internal medicine
Outcome results
None listed